Botulinum toxin A for children with salivary control problems

Area of Science:

• Pediatric Neurology
• Otolaryngology
• Pharmacology

Background:

• Sialorrhea, or excessive drooling, significantly impacts quality of life in children with neurological impairments.
• Pharmacological therapies often have limited efficacy or significant side effects for managing pediatric sialorrhea.
• Botulinum toxin A (BtA) has emerged as a potential therapeutic option for intractable sialorrhea.

Purpose of the Study:

• To review the efficacy and safety of botulinum toxin A (BtA) injections for saliva control in pediatric patients.
• To identify factors predicting a successful response to BtA treatment for sialorrhea.

Main Methods:

• A retrospective case series of 97 children treated for sialorrhea at a tertiary pediatric hospital.
• BtA injections were administered to parotid and submandibular glands, primarily under local anesthesia.
• Data collected included patient demographics, diagnosis, BtA dosage, response, duration, and complications.

Main Results:

• Of 175 BtA doses administered, 62% were effective, 8% partially effective, and 29% ineffective.
• The mean duration of response was 4 months, with complications occurring in 10.9% of injections.
• Male gender and cerebral palsy were statistically significant predictors of a better response to BtA.

Conclusions:

• Botulinum toxin A injections are a safe and effective treatment for pediatric sialorrhea, with or without ultrasound guidance.
• Dysphagia is the primary adverse effect, particularly in children with existing swallowing difficulties.
• While male sex and cerebral palsy are positive predictors, BtA can benefit a broader pediatric population, and initial responders often show sustained benefit.